Hertraz 440 (Trastuzumab Vials) 440 mg

Trastuzumab works by binding to the HER2 receptor on cancer cells, inhibiting downstream signaling and mediating antibody-dependent cellular cytotoxicity. This action prevents the proliferation of cancer cells that overexpress HER2, thereby slowing tumor growth and progression. It is a targeted therapy designed to specifically attack cancer cells with HER2 overexpression.

The dosage of Hertraz 440 is determined by a healthcare professional based on the patient's condition, body weight, and response to treatment. The initial loading dose and subsequent maintenance doses are calculated according to the patient's specific needs. It is important to follow the prescribed dosage and administration schedule as directed by the healthcare provider.

Hertraz 440 should be avoided during pregnancy unless the potential benefits outweigh the risks, as it may affect fetal development. Women should avoid breastfeeding during treatment with trastuzumab. It is important to discuss the potential risks and benefits with a healthcare professional before starting treatment.

To order Hertraz 440 from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask the buyer to confirm trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

Hertraz 440 is a humanized monoclonal antibody that specifically targets the HER2 receptor. It is similar to other HER2-targeted therapies in its mechanism of action but may have differences in efficacy, safety profile, and administration schedule. The choice of therapy depends on the patient's specific condition and response to treatment, as determined by a healthcare professional.

Hertraz 440 should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. The reconstituted solution should be used immediately and any unused portion must be discarded. It is important to follow the storage and handling instructions provided by the manufacturer to ensure the medication's effectiveness and safety.

Hertraz 440 is administered as an intravenous infusion by a healthcare professional. The initial loading dose is typically administered over 90 minutes, and subsequent doses may be administered over a shorter period if well tolerated. Patients should be monitored for infusion-related reactions during and after administration.

The most serious risks associated with Hertraz 440 include cardiac dysfunction, infusion-related reactions, neutropenia, and pulmonary adverse reactions. Regular cardiac monitoring and close observation for signs of infusion-related reactions are essential. Patients should report any unusual symptoms to their healthcare provider immediately.

Hertraz 440 is not recommended for children below 18 years of age and pregnant women due to insufficient safety and efficacy data. It should be used with caution in patients with pre-existing cardiac conditions and those who have had severe infusion-related reactions to trastuzumab or other monoclonal antibodies. Always consult a healthcare professional before starting treatment.